August 25, 2023 August 25, 2023Categories Active Clinical TrialsAmended Trial: Eligibility Expands in the EA8191/INDICATE Trial for Patients with Prostate CancerThe changes broaden eligibility for prostate cancer patients and make baseline scanning easier for sites in this phase 3 trial using PET imaging to guide treatment for recurrence
August 25, 2023 August 25, 2023Categories Trial ResultsTrial Results: ECOG-ACRIN Research Round-UpSummaries of recently published ECOG-ACRIN research results
October 13, 2022 October 13, 2022Categories Trial ResultsTrial Results: ECOG-ACRIN Research Round-UpSummaries of recently published ECOG-ACRIN research results
August 16, 2022 August 16, 2022Categories Active Clinical TrialsTrial Spotlight: Neha Vapiwala on the EA8191/INDICATE Study for Prostate CancerThis phase 3 study is using PET/CT imaging to guide treatment for patients with post-prostatectomy biochemical recurrence
August 16, 2022 August 16, 2022Categories News in BriefNews in Brief, August 2022Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more
April 15, 2022 April 15, 2022Categories News in BriefNews in Brief, April 2022Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more
August 17, 2021 August 17, 2021Categories Active Clinical TrialsNow Enrolling: EA8184 for Prostate CancerThis phase II study is testing the effects and safety of green tea catechins (GTC) as a chemopreventive agent
January 25, 2021 January 25, 2021Categories Active Clinical TrialsNow Enrolling: EA8183 / ERADICATE for Patients with Localized Prostate CancerThis phase III study, led by Dr. Alicia Morgans, is exploring a new treatment option for patients with prostate cancer with high-risk features
December 14, 2020 December 14, 2020Categories Active Clinical TrialsNow Enrolling: ECOG-ACRIN Opened Five New Trials in OctoberThe five phase III trials span different cancer types: prostate, leukemia, anal, lung, and myeloma